Conditions: Prostate Cancer
Keywords: recurrent prostate cancer stage IV prostate cancer Prostate-Specific Antigen
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 64
Healthy volunteers: no

Brief summary:
This phase II trial studies how well hydroxychloroquine works in treating patients with previously treated prostate cancer. Autophagy destroys proteins and other substances in cells and may be used by prostate cancer cells to survive. Hydroxychloroquine, which blocks autophagy, may slow the growth of and possibly kill prostate cancer cells.

Detailed description:

Arms:
arm 1: Hydroxychloroquine - 400 mg (cohort A) Hydroxychloroquine - 600 mg (cohort B)

Interventions: intervention 1: hydroxychloroquine
Intervention descriptions: intervention 1: Hydroxychloroquine will be taken at a dose of 200 mg twice per day in the first 27 patients (cohort A). Once cohort A completed, the dose of hydroxychloroquine will then be increased to 600mg per day (200mg three times per day)(cohort B).

Protocol document: